Parmax Pharma Reaches New 52-Week High, Outperforms Sector by 9.5%

Parmax Pharma, a microcap pharmaceutical company, has recently reached a new 52-week high on July 15, 2024. The stock has been performing well in the market, with a strong sell call by MarketsMOJO.

On the day of the new high, the stock opened with a gain of 4.27% and touched an intraday high of Rs 43.3, outperforming the sector by 9.5%. It has also been gaining for the last two days, with a rise of 25.44% in returns during this period. However, it also experienced high volatility, with an intraday volatility of 7.63%.

Parmax Pharma's performance over the past year has been impressive, with a 45.73% increase compared to the Sensex's 22.08% performance. The stock is currently trading higher than its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages.

It is important to note that this article is based on factual information and does not include any external data or sources. It is not intended to provide any recommendations or discuss potential future developments. Parmax Pharma's recent success in the market is a reflection of its strong performance and should be considered by investors when making their own decisions.